BioNxt Solutions (BNXT) AI Stock Analysis

• Market Cap: $100.85M
• Dividend Yield: N/A
• Average Volume (3M): 140.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.63
• Revenue Growth: -29.29%
• EPS Growth: 12.89%
• Country: CA
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 120,062,750
• 10 Day Avg. Volume: 155,685
• 30 Day Avg. Volume: 140,414
• PEG Ratio: 0.20
• Price to Book (P/B): -5.39
• Price to Sales (P/S): 1568.84
• P/FCF Ratio: -13.95
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 3.33K
• Enterprise Value/Gross Profit: -2.99K
• Enterprise Value/Ebitda: -14.62
• 1Y Price Target: $1.00
• Price Target Upside: 19.52% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: C$1.00 ▲(19.05% Upside)

BioNxt Solutions' overall stock score is primarily impacted by its poor financial performance, characterized by consistent losses and high leverage. Technical analysis provides some support with mixed signals, but the negative valuation metrics further weigh down the score. The absence of earnings call insights and corporate events leaves the financial and technical factors as the primary determinants of the score.

BioNxt Solutions Business Overview & Revenue Model

Company Description

BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

How the Company Makes Money

BioNxt Solutions generates revenue through the development and commercialization of its proprietary technologies and solutions in the life sciences field. Key revenue streams include licensing agreements, partnerships with pharmaceutical and biotechnology companies, and direct sales of medical devices or pharmaceuticals. The company may also receive research and development grants, milestone payments, and royalties from its collaborations. Strategic partnerships play a significant role in its income, allowing BioNxt Solutions to leverage external expertise and resources to bring its innovations to market more efficiently.

BioNxt Solutions Financial Statement Overview

Summary

BioNxt Solutions is facing significant financial challenges across all verticals. The income statement shows consistent losses, the balance sheet reveals high leverage and negative equity, and the cash flow statement indicates poor cash generation. The company needs strategic restructuring and improved operational efficiency to stabilize its financial position.

Income Statement

BioNxt Solutions has been experiencing declining revenues over the past few years, with a significant drop from 2023 to 2024. Despite a gross profit margin of 100% in 2024, the company continues to face substantial net losses, indicating poor control over operating expenses and high negative EBIT and EBITDA margins. The negative net profit margin suggests persistent profitability challenges.

Balance Sheet

The company has a negative stockholders' equity, indicating that its liabilities exceed its assets, which is a major financial risk. The debt-to-equity ratio is not meaningful due to negative equity, but the high level of debt relative to assets suggests leverage concerns. Return on equity is negative due to net losses, and the equity ratio is negative, signifying financial instability.

Cash Flow

BioNxt Solutions' cash flow situation is troubling, with consistently negative free cash flow and operating cash flow. The free cash flow growth rate is negative, indicating worsening cash flow generation. The operating and free cash flow to net income ratios are not favorable, reflecting inefficiencies in converting income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.66K	26.98K	372.25K	297.44K	286.50K	345.65K
Gross Profit	-24.11K	26.98K	372.25K	195.62K	199.48K	345.65K
EBITDA	-4.93M	-4.32M	-6.48M	-11.51M	-19.19M	-16.05M
Net Income	-6.04M	-5.31M	-7.72M	-12.38M	-20.64M	-16.89M
Balance Sheet
Total Assets	613.61K	569.36K	1.27M	1.61M	9.73M	8.28M
Cash, Cash Equivalents and Short-Term Investments	4.24K	32.35K	363.65K	136.20K	1.35M	2.58M
Total Debt	7.06M	4.28M	4.89M	4.37M	5.46M	3.31M
Total Liabilities	9.02M	8.43M	6.55M	5.74M	8.06M	4.28M
Stockholders Equity	-8.41M	-7.86M	-5.28M	-4.13M	1.67M	4.01M
Cash Flow
Free Cash Flow	-3.39M	-3.03M	-5.37M	-6.23M	-12.61M	-10.36M
Operating Cash Flow	-3.39M	-3.03M	-5.17M	-6.23M	-12.16M	-10.20M
Investing Cash Flow	84.99K	56.21K	100.84K	-3.86K	-5.31M	-156.47K
Financing Cash Flow	3.00M	2.64M	5.29M	5.02M	16.23M	12.65M

BioNxt Solutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Positive. The current price of 0.84 is below the 20-day moving average (MA) of 0.88, below the 50-day MA of 0.84, and above the 200-day MA of 0.57, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.31 is Neutral, neither overbought nor oversold. The STOCH value of 87.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BNXT.

BioNxt Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	58 Neutral	89.36M	67.40	1.52%	―	0.03%	-17.30%
MPH	49 Neutral	11.48M	-8.49	-7.39%	―	10.84%	48.57%
RVV	46 Neutral	6.28M	-1.56	―	―	―	15.79%
BNXT	45 Neutral	$100.85M	―	87.69%	―	-29.29%	12.89%
INNO	45 Neutral	65.23M	-29.29	-37.47%	―	21.46%	65.70%
MVMD	35 Underperform	5.29M	-0.71	―	―	-46.59%	9.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BioNxt Solutions Corporate Events

BioNxt Solutions Settles Debt with Share Issuance and Cash Payment

BioNxt Solutions Inc. has entered into a debt settlement agreement with a creditor to address $225,010 in outstanding debt. The settlement involves issuing 112,505 common shares and a cash payment of $112,505, subject to regulatory approvals. This move reflects BioNxt’s strategic financial management and could enhance its market positioning by resolving outstanding liabilities.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Enhances Market Presence with OTCQB Up-Listing

BioNxt Solutions Inc. has successfully upgraded its listing to the OTCQB market, allowing its common shares to be accessible to a broader group of US investors under the ticker symbol ‘BNXTF’. This move is seen as a positive step in enhancing the company’s market presence and shareholder value, supported by its ongoing drug development programs in Europe and a pending chemotherapy drug delivery deal in North America. The up-listing is expected to improve the liquidity and trading availability of BioNxt’s shares, aligning with the company’s strategic growth and compliance with OTCQB standards.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Accelerates U.S. Patent for MS Drug and Secures Broad Platform IP

BioNxt Solutions Inc. has initiated a fast-track process for a U.S. patent application for its novel sublingual thin-film cladribine formulation, BNT23001, targeting multiple sclerosis. This strategic move aims to secure patent protection and enhance BioNxt’s intellectual property position, facilitating clinical development and potential commercial partnerships. Additionally, BioNxt has secured a broad international patent for its sublingual thin-film delivery platform, providing long-term exclusivity for a range of drug compounds and therapeutic indications, which could significantly impact its market positioning and stakeholder interests.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Boosts Investor Relations with Strategic Engagements in Germany

BioNxt Solutions Inc. has engaged two firms, Apaton Finance GmbH and Cayo Ventures GmbH, to enhance its investor relations and brand visibility in Germany. Apaton will focus on disseminating company news and engaging stakeholders through social media and email, while Cayo will provide digital marketing services to drive traffic to BioNxt’s website. These engagements are expected to bolster BioNxt’s market presence and investor engagement in the European market, potentially impacting its operations and stakeholder relations positively.

The most recent analyst rating on (TSE:BNXT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.

BioNxt Solutions Completes Oversubscribed Convertible Debenture Offering

BioNxt Solutions Inc. has successfully closed the final tranche of its oversubscribed private placement of convertible debenture units, raising a total of $1,250,400. The funds will be used for product development, commercialization, intellectual property filings, and general working capital, strengthening BioNxt’s market position and supporting its focus on advancing regulatory approvals and commercialization efforts in European markets.

BioNxt Solutions Secures Pending Patent Grants for MS Treatment in Europe and Eurasia

BioNxt Solutions has made significant strides in its global patent portfolio, with pending patent grants in Europe and Eurasia for its sublingual Cladribine-based treatment for relapsing-remitting multiple sclerosis (RRMS). The acceptance of these patents marks a critical step in protecting BioNxt’s innovative drug delivery technology, which optimizes drug absorption and improves patient compliance. This development is expected to enhance BioNxt’s commercial value by enabling regional exclusivity and supporting future licensing and partnership opportunities. The company is also preparing for GMP manufacturing and clinical studies in Europe to advance regulatory filings and commercialization efforts.

BioNxt Solutions Closes First Tranche of Convertible Debenture Private Placement

BioNxt Solutions Inc. has successfully closed the first tranche of its non-brokered private placement of convertible debenture units, raising gross proceeds of $1,009,200. The funds will be used for product development, commercialization, intellectual property filings, and general working capital, potentially enhancing the company’s market position and operational capabilities.

BioNxt Achieves Key Milestone with Cladribine Thin-Film Prototype for MS Treatment

BioNxt Solutions Inc. has successfully formulated a sublingual thin-film prototype for its lead clinical stage candidate, BNT23001, using cladribine for the treatment of multiple sclerosis. This milestone strengthens BioNxt’s position in the drug delivery industry by offering a patient-centric alternative to conventional oral tablets, potentially improving treatment adherence for MS patients. The company is advancing towards clinical trials and regulatory readiness, with ongoing efforts in intellectual property protection and potential out-licensing opportunities.

BioNxt Solutions Launches $1.2M Convertible Debenture Offering

BioNxt Solutions Inc. announced a non-brokered private placement of convertible debenture units to raise up to $1,200,000. The proceeds will be used for product development, commercialization, intellectual property filings, and general working capital, potentially impacting the company’s growth and market position in the bioscience industry.

BioNxt Solutions Resumes Trading as Cease Trade Order Revoked

BioNxt Solutions Inc. announced the revocation of a management cease trade order by the British Columbia Securities Commission, following the successful filing of its annual financial documents. This development allows the company’s management to resume trading its securities, potentially stabilizing investor confidence and enhancing the company’s market operations.